Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 11, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 6,050,000 ordinary shares.
- Purchase Price: 1,293.5 pence per share.
- Treasury Holdings: 436,789,158 shares (representing 7.82% of total voting rights).
- Shares in Issue: 5,587,858,369 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 6,050,000 shares on October 11, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against a prior period for financial performance.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future operations, or discussion of risks and contingencies. It strictly serves as a notification of the share repurchase in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007, and compliance with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total cost of the repurchase (6,050,000 shares at 1,293.5 pence).
- Confirm the updated percentage of Treasury shares relative to total voting rights (7.82%).
- Check the current number of shares in issue for dividend and voting calculations (5,587,858,369).
- Note that this filing does not contain quarterly or annual financial results.